Denali Therapeutics Inc. (DNLI)
NASDAQ · Healthcare
Denali Therapeutics Inc. EBITDA 2016–2025
Denali Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2016 to 2024. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Denali Therapeutics Inc. ebitda for the quarter ending March 31, 2024 was -115.6 M, a 4.32% increase year-over-year.
- Denali Therapeutics Inc. ebitda for the twelve months ending March 31, 2024 was -359.9 M.
- Denali Therapeutics Inc. annual ebitda for 2025 was -544.2 M, a 13.47% increase from 2024.
- Denali Therapeutics Inc. annual ebitda for 2024 was -479.5 M, a 166.45% increase from 2023.
- Denali Therapeutics Inc. annual ebitda for 2023 was -180.0 M, a 45.52% decrease from 2022.
- Denali Therapeutics Inc. annual ebitda for 2022 was -330.4 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Denali Therapeutics Inc. EBITDA — FAQ
Denali Therapeutics Inc. (DNLI) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see DNLI's ebitda history?
The chart and table above show Denali Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.